Comparable results have been achieved in a retrospective clinical study where the Her2-overexpressing metastatic breast cancer patients, subjected to the concurrent treatment with β-blocker propranolol and trastuzumab, showed an improvement of progression-free survival and overall survival, underling the strong interplay between the β2-AR and EGFR pathways [16]. This evidence concerns the gene ERBB2 and breast cancer.